The analytical performance of the Dimension XL clinical chemical system was evaluated. The XL is the latest addition to the Dimension family of instruments; it is a random access analyser with a throughput up to 740 tests/hour. Regression analysis of method comparison studies with Dimension AR yielded slopes of 0.93 to 1.03 and correlation coefficients >/=0.96 for 28 assays. Excellent precision performance was also observed. New instrument features of the XL are discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2548115 | PMC |
http://dx.doi.org/10.1155/S1463924697000023 | DOI Listing |
Curr Med Chem
January 2025
Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Background: Infertility was often considered a female issue, but male infertility emerged significantly after the Covid-19 pandemic. Hence, assessments are crucial for planning policies on health care and family planning and reasons thereof post vaccinations.
Material And Methods: The present study was a case-control, dual-centers, prospective study with normal sperm parameters.
Front Psychol
January 2025
Department of Anaesthesiology, School of Clinical Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China.
Background: Perceived pain intensity is an important determinant of health-related quality of life. A lack of studies has investigated the co-influences of physical and psychosocial risk factors on perceived pain intensity and the shifts in effects after pandemic. As a post-COVID symptom, it is important to re-assess the risk factors for post-COVID heath care.
View Article and Find Full Text PDFBMJ Oncol
May 2024
Centre for Health Informatics, Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Objective: Investigate whether routinely collected electronic patient-reported outcome measures (ePROMs) add prognostic value to clinical and tumour characteristics for adults with advanced non-small cell lung cancer (NSCLC) receiving immunotherapy.
Methods And Analysis: We retrospectively analysed data from adults with advanced NSCLC commencing immunotherapy between April 2019 and June 2022. Prognostic factors were ePROMs on quality of life (EuroQoL five-dimension five-level (EQ-5D-5L); EuroQoL Visual Analogue Scale (EQ-VAS)) and symptoms (patient-reported version of the Common Terminology Criteria for Adverse Events v5.
Asia Pac J Oncol Nurs
December 2025
Department of Nursing, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Objective: This study was aimed at investigating the network structures of fatigue symptoms in patients with advanced cancer, with a focus on identifying the central symptom-an aspect crucial for targeted and effective fatigue symptom management.
Methods: In this cross-sectional study, patients with advanced cancer were recruited from the cancer treatment center of a tertiary hospital in China between January and December of 2022. Symptom occurrence and severity were assessed with the Cancer Fatigue Scale.
BMC Sports Sci Med Rehabil
January 2025
Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Science, Enghelab St, Pich-e-Shemiran, Tehran, Iran.
Background: Chronic ankle instability (CAI) is characterized by recurrent sprains and persistent symptoms, which impair postural control. This study evaluates the diagnostic utility of various linear and nonlinear postural stability measures in distinguishing individuals with CAI from healthy controls.
Methods: Postural stability was assessed in 24 participants (12 with CAI and 12 healthy controls) using a force platform under four conditions: hard surface with eyes open, hard surface with eyes closed, soft surface with eyes open, and soft surface with eyes closed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!